UNASSIGNED: The author performed bridged repair with an ovine reinforced biologic in 19 consecutive high-risk patients over a 5-year period. In all cases the reinforced biologic was used as an underlay.
UNASSIGNED: Of the 19 patients, six (32%) experienced a surgical site occurrence including infection, seroma, abscess, fistula, bioloma, or bowel obstruction. Three patients (16%) had recurrences with two out of three of the recurrences occurring within 6 months of surgery.
UNASSIGNED: Rates of SSO\'s and recurrences using ovine reinforced tissue matrix (RTM) were in line with or better than other published studies of bridged repair utilizing biologic or synthetic mesh reinforcement. Ovine RTM\'s should therefore be considered in complex large ventral hernia repairs.
UNASSIGNED:作者在5年的时间内对19例连续的高危患者进行了用绵羊增强生物制剂的桥接修复。在所有情况下,都将增强的生物制品用作底层。
未经证实:在19名患者中,6人(32%)经历了包括感染在内的手术部位,血清肿,脓肿,瘘管,bioloma,或者肠梗阻.三名患者(16%)复发,其中三分之二的复发发生在手术后6个月内。
UNASSIGNED:使用绵羊增强组织基质(RTM)的SSO和复发率与其他已发表的使用生物或合成网状增强的桥接修复研究一致或更好。因此,在复杂的大型腹侧疝修补术中应考虑绵羊RTM。